Business Context and Reporting Period
Company: Incyte Genomics, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2002
Business Overview: Incyte is a drug discovery company developing proprietary genomic information and applying expertise in medicinal chemistry to discover novel small molecule and protein therapeutics. The company markets genomic and proteomic information to pharmaceutical and biotechnology companies. During 2001, the company exited several product lines (microarray products, genomic screening, contract sequencing) to focus on therapeutic discovery and database licensing.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2002 | Nine Months Ended Sep 30, 2002 | Balance Sheet (Sep 30, 2002) |
|---|---|---|---|
| Revenues | $22,390 | $80,463 | - |
| Net Loss | $(38,411) | $(69,393) | - |
| Loss Per Share (Basic/Diluted) | $(0.57) | $(1.03) | - |
| Operating Expenses | $59,854 | $159,601 | - |
| Cash and Cash Equivalents | - | - | $15,736 |
| Marketable Securities | - | - | $437,093 |
| Total Assets | - | - | $603,054 |
| Convertible Subordinated Notes | - | - | $172,143 |
| Accumulated Deficit | - | - | $(337,532) |
Cash Flow (Nine Months Ended Sep 30, 2002):
- Net cash used in operating activities: $(38,664) thousand
- Net cash provided by investing activities: $9,969 thousand
- Net cash provided by financing activities: $1,299 thousand
Material Changes vs. Prior Period
- Revenue Decline: Revenues for the nine months ended September 30, 2002, decreased to $80.5 million from $164.5 million in the prior year. This 51% decline is primarily due to the exit of custom genomics products and services, fewer intellectual property licenses, and reduced database revenues driven by spending cuts in the pharmaceutical industry.
- Increased Net Loss: Net loss for the nine months increased to $69.4 million from $38.0 million in the prior year. The increase is attributed to higher operating losses, though offset by the absence of the $130.4 million non-recurring restructuring and impairment charges recorded in the fourth quarter of 2001.
- Expense Reduction: Total operating expenses decreased to $159.6 million (nine months 2002) from $220.6 million (nine months 2001), reflecting the wind-down of exited product lines and infrastructure reductions.
- Asset Impairment: The company recorded an $8.1 million impairment charge in the third quarter of 2002 related to prepaid licenses and software.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- Strategic Shift: The company is focusing on therapeutic discovery and development and database licensing. It expects to incur losses in 2002 and future periods as it invests in drug development.
- Cost Reduction Plan: On November 12, 2002, the company announced a plan to reduce 2003 expenditures, primarily in R&D, through spending reductions, office consolidations, and a workforce reduction of approximately 37% (approx. 260 employees). This is expected to result in a charge of up to $40 million in the fourth quarter of 2002.
- Acquisition: The company entered into a definitive agreement to acquire Maxia Pharmaceuticals, Inc., for up to $28.3 million in cash/stock plus $14 million in milestones. A charge may be taken upon closing if the purchase price is allocated to in-process R&D.
- Liquidity: Management believes existing resources ($452.8 million in cash and marketable securities) are adequate for at least the next twelve months.
Risks and Contingencies
- Patent Litigation: Ongoing litigation with Invitrogen Corporation regarding patent infringement. The company cannot estimate potential losses but expects substantial future legal costs. A settlement with Affymetrix was reached in late 2001.
- Debt Obligations: The company has $172.1 million in convertible subordinated notes due in 2007. A deficiency of earnings available to cover fixed charges of $68.5 million was reported for the nine months ended September 30, 2002.
- Related Party Transactions: Significant transactions exist with companies where directors hold interests (e.g., Genomic Health, Iconix, Epoch, Medarex, Maxia), including equity investments and revenue agreements.
Investor Verification Checklist
- Workforce Reduction Impact: Verify the execution of the announced 37% workforce reduction and the associated $40 million charge in Q4 2002.
- Maxia Acquisition: Monitor the closing conditions for the Maxia Pharmaceuticals acquisition and the potential accounting treatment (charge) for in-process R&D.
- Invitrogen Litigation: Track developments in the patent infringement lawsuit with Invitrogen, as the outcome could result in significant damages or licensing requirements.
- Cash Burn Rate: Assess the sustainability of the cash position ($15.7 million cash + $437.1 million marketable securities) against the projected $40 million restructuring charge and ongoing R&D expenditures.
- Revenue Concentration: Review the dependency on a small number of customers (one customer contributed 15% of Q3 2002 revenue) and the impact of pharmaceutical industry spending cuts.